Excluding the study of Venugopalet et al. [14], the CR rate of R/R AML patients with IDH mutations who received IDH inhibitor alone was 21% [95% CI 0.17–0.24, I2 = 0%]. Here, IDH2 is linked to acute myeloid leukemia.